Undisclosed Engineered Antigen Program(s)

About Fletcher Biosciences

Fletcher Biosciences is a private, pre-clinical stage biotech leveraging a novel protein engineering platform to develop next-generation immunotherapies. The company's approach involves redesigning natural antigen scaffolds to create biologics capable of precisely targeting and eliminating pathogenic T cells driving autoimmune disorders. While still early-stage, its technology holds promise for addressing complex immune-mediated diseases, though it faces significant scientific and competitive risks inherent to the field. The company appears to be in a venture-backed R&D phase, building its platform and pipeline.

Therapeutic Areas

Other Autoimmune Diseases (unspecified) Drugs